Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Topics Stocks

3 Cash-Producing Stocks with Open Questions

October 29, 2025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 28, 2025

Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk ↗

Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock ↗

October 20, 2025

Via Benzinga

October 20, 2025

Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor...

Via Stocktwits

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

October 19, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm

October 16, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 7.7% in the afternoon session after it submitted a Marketing Authorization Application to the European Medicines Agency for its...

Corcept (CORT) Shares Skyrocket, What You Need To Know

October 15, 2025

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

October 14, 2025

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

3 High-Flying Stocks We Approach with Caution

October 13, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

3 Profitable Stocks That Concern Us

October 10, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 12.3% in the morning session after reports of a significant stock sale by a top executive surfaced. The company's Chief Development...

Why Corcept (CORT) Shares Are Falling Today

October 10, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Topics Artificial Intelligence

1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm

October 07, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

3 Low-Volatility Stocks We Think Twice About

October 03, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 2.1% in the afternoon session after the company announced a specialty pharmacy partnership with Curant Health. Corcept has selected...

Topics Government

Why Corcept (CORT) Stock Is Trading Up Today

October 01, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Topics ETFs

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Via Benzinga

1 Momentum Stock with Competitive Advantages and 2 We Find Risky

September 26, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent...

What Analysts Are Saying About Corcept Therapeutics Stock ↗

September 25, 2025

Via Benzinga

Why Are Corcept (CORT) Shares Soaring Today

September 23, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 5.4% in the afternoon session after the company announced it would present new data from its pivotal Phase 3 ROSELLA trial and that...

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Topics Artificial Intelligence

September 22, 2025

Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment

September 15, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and worst...

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Topics Artificial Intelligence Intellectual Property

September 10, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

3 Cash-Producing Stocks That Concern Us

September 09, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy ↗

August 20, 2025

Discover Corcept Therapeutics (CORT), an affordable growth stock with strong revenue growth, high profitability, and a compelling valuation within the pharmaceuticals sector.

Via Chartmill

Corcept Therapeutics Inc (NASDAQ:CORT): A Strong Growth Stock with Solid Fundamentals and Technical Upside ↗

August 18, 2025

Corcept Therapeutics (CORT) shows strong growth, profitability, and technical momentum, making it a top pick for investors seeking high-potential stocks.

Via Chartmill

3 Cash-Heavy Stocks with Warning Signs

August 18, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue...

CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook

August 13, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

2 Growth Stocks Set to Flourishand 1 We Avoid

August 12, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

3 Low-Volatility Stocks That Fall Short

August 04, 2025